Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milnacipran

Synapse

Volumn 65, Issue 7, 2011, Pages 652-657

  Rahmadi, Mahardian ^a   Narita, Minoru ^a   Yamashita, Akira ^a   Imai, Satoshi ^a   Kuzumaki, Naoko ^a   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Orexin; Sleep disturbance; SNRI; SSRI

Indexed keywords

HISTAMINE H1 RECEPTOR; HISTIDINE DECARBOXYLASE; MILNACIPRAN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; PAROXETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; FRONTAL CORTEX; HYPOTHALAMUS; MALE; MOUSE; NONHUMAN; NONREM SLEEP; PRIORITY JOURNAL; SLEEP DISORDER;

ANIMALS; BRAIN; CYCLOPROPANES; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; HISTAMINE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; NEUROPEPTIDES; PAROXETINE; RECEPTORS, HISTAMINE; RECEPTORS, NEUROPEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN UPTAKE INHIBITORS; SLEEP; SLEEP DISORDERS; SYNAPTIC TRANSMISSION;

EID: 79954415023     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20893     Document Type: Article

References (15)

1. Black K, Shea C, Dursun S, Kutcher S. 2000. Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria. J Psychiatry Neurosci 25: 255-261.
2. Dell'Osso B, Nestadt G, Allen A, Hollander E. 2006. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry 67: 600-610.
3. Feige B, Voderholzer U, Riemann D, Dittmann R, Hohagen F, Berger M. 2002. Fluoxetine and Sleep EEG: Effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 26: 246-258.
4. Hamon M, Bourgoin S. 2006. Pharmacological profile of antidepressants: A likely basis for their efficacy and side effects? Eur Neuropsychopharmacol 16: S625-S632.
5. Hass H, Panula P. 2003. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 4: 121-130.
6. Huang ZL, Qu WM, Li WD, Mochizuki T, Eguchi N, Watanabe T, Urade Y, Hayaishi O. 2001. Aurosal effect of orexin A depends on activation of histaminergic system. Proc Natl Acad Sci USA 98: 9965-9970.
7. Narita M, Mizoguchi H, Suzuki T, Narita M, Dun NJ, Imai S, Yajima Y, Nagase H, Suzuki T, Tseng LF. 2001. Enhanced mu-opioid responses in the spinal cord of mice lacing protein kinase Cgamma isoform. J Biol Chem 276: 15409-15414.
8. Olivier JDA, Blom T, Arentsen T, Homberg JR. The age-dependent effects of selective serotonin reuptake inhibitor in human and rodents: A review. Prog Neuro-Psychopharmacol Biol Psychiatry (in press).
9. Pace-Schott EF, Hobson JA. 2002. The neurobiology of sleep: Genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3: 591-605.
10. Panula P, Yang HYT, Costa R. 1984. Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci USA 81: 2572-2576.
11. Paxinos G, Franklin KBJ. 2004. The mouse brain in stereotaxic coordinates, 2nd ed. San Diego, CA: Academic Press.
12. Preskorn SH, Ross R, Stanga CY. 2004. Selective serotonin reuptake inhibitor. In: Preskorn SH, Feighner HP, Stanga CY, Ross R, editros. Antidepressants: Past, present, and future. Berlin: Springer. p 241-262.
13. Tao R, Ma Z, McKenna JT, Thakkar MM, Winston S, Strecker RE, McCarley RW. 2006. Differential effect of orexins (hypocretins) on serotonin release in the dorsal and median raphe nuclei of freely behaving rats. Neuroscience 141: 1101-1105.
14. Torres GE, Gainetdinov RR, Caro MG. 2003. Plasma membran monoamine transporters: Structure, regulation and function. Nat Rev Neurosci 4: 13-25.
15. Yamanaka A, Tsujino N, Funahashi H, Honda, KGuan JL, Wang QP, Tominaga M, Goto K, Shioda S, Sakurai T. 2002. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 290: 1237-1245.